ZIVO Bioscience (NASDAQ:ZIVO – Get Free Report) and Inhibikase Therapeutics (NYSE:IKT – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.
Valuation and Earnings
This table compares ZIVO Bioscience and Inhibikase Therapeutics’ gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ZIVO Bioscience | $30,000.00 | 924.07 | -$7.78 million | ($3.80) | -2.20 |
| Inhibikase Therapeutics | $260,000.00 | 44.29 | -$19.03 million | ($3.33) | -0.48 |
ZIVO Bioscience has higher earnings, but lower revenue than Inhibikase Therapeutics. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Inhibikase Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ZIVO Bioscience | 0 | 1 | 0 | 0 | 2.00 |
| Inhibikase Therapeutics | 0 | 0 | 1 | 0 | 3.00 |
Inhibikase Therapeutics has a consensus price target of $23.00, suggesting a potential upside of 1,342.01%. Given Inhibikase Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Inhibikase Therapeutics is more favorable than ZIVO Bioscience.
Risk and Volatility
ZIVO Bioscience has a beta of 0.23, meaning that its share price is 77% less volatile than the S&P 500. Comparatively, Inhibikase Therapeutics has a beta of 1.32, meaning that its share price is 32% more volatile than the S&P 500.
Institutional and Insider Ownership
12.8% of ZIVO Bioscience shares are held by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are held by institutional investors. 21.5% of ZIVO Bioscience shares are held by insiders. Comparatively, 14.7% of Inhibikase Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares ZIVO Bioscience and Inhibikase Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ZIVO Bioscience | -11,068.75% | N/A | -677.15% |
| Inhibikase Therapeutics | N/A | -147.03% | -116.72% |
Summary
Inhibikase Therapeutics beats ZIVO Bioscience on 8 of the 13 factors compared between the two stocks.
About ZIVO Bioscience
ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan.
About Inhibikase Therapeutics
Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.
Receive News & Ratings for ZIVO Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIVO Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
